PUBLISHED ON: May 12, 2010 | Duration: 10 min, 53 sec
Atul Sobti, MD of Ranbaxy, says the company's Q1 profits soared on account of launch of generic version of a blockbuster drug in the US and heavy foreign exchange gains. Sobti says he sees growth coming from the US, Africa, CIS and Indian markets.
